| answer text |
<p>For breast implants and other implantable materials, the Medicines and Healthcare
products Regulatory Agency (MHRA) is currently considering what information should
be provided to the patient at the point of consent and on receipt of the implant.
The new regulatory approach is not yet finalised but warnings, precautions or measures
to be taken by the patient or a healthcare professional are being considered as is
a caution that risk may emerge during use of an implantable device, including, where
appropriate, on Breast Implant Associated Anaplastic Large Cell Lymphoma. Further
information about the outcome of the public consultation on the regulation of medical
devices is expected to be published early this year.</p>
|
 |
